2014
DOI: 10.1200/jco.2014.32.3_suppl.548
|View full text |Cite
|
Sign up to set email alerts
|

Planned interim analysis of phase II study of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353.

Abstract: 548 Background: Inhibition of the MEK/ERK pathway through Raf has been shown to resensitize tumor cells resistant to chemotherapy. Sorafenib (Sor) is an oral multi-tyrosine kinase inhibitor (TKI) affecting tumor proliferation and angiogenesis through inhibition of the Ras/Raf/MEK/ERK, VEGF, and PDGF pathways. A similar TKI, regorafenib, has efficacy as monotherapy in advanced mCRC. Demonstrating activity of this compound class with standard cytotoxic therapy represents a clinical unmet need. Methods: Eligible… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2015
2015
2015
2015

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Sorafenib RAF1, BRAF, PDGFRβ, VEGFR-2, c-kit I-II Sorafenib plus irinotecan 64.9% SD [13] II Sorafenib plus capecitabine 44% SD [14] Vemurafenib BRAF(V600E) Pilot study Vemurafenib plus panitumumab 13% PR 53% SD [15] I Vemurafenib plus cetuximab and irinotecan 35% PR [16] Selumetinib MEK1 IIR Selumetinib vs capecitabine 29% SD 3% PR 43% SD [17] II Selumetinib plus irinotecan 10% PR 52% SD [18] Dabrafenib BRAF(V600E), BRAF, CRAF I-II Dabrafenib plus trametinib † 3% CR 9% PR [19] Trametinib MEK1, MEK2…”
Section: Ras-raf-mek-erk Pathway Inhibitorsmentioning
confidence: 99%
See 1 more Smart Citation
“…Sorafenib RAF1, BRAF, PDGFRβ, VEGFR-2, c-kit I-II Sorafenib plus irinotecan 64.9% SD [13] II Sorafenib plus capecitabine 44% SD [14] Vemurafenib BRAF(V600E) Pilot study Vemurafenib plus panitumumab 13% PR 53% SD [15] I Vemurafenib plus cetuximab and irinotecan 35% PR [16] Selumetinib MEK1 IIR Selumetinib vs capecitabine 29% SD 3% PR 43% SD [17] II Selumetinib plus irinotecan 10% PR 52% SD [18] Dabrafenib BRAF(V600E), BRAF, CRAF I-II Dabrafenib plus trametinib † 3% CR 9% PR [19] Trametinib MEK1, MEK2…”
Section: Ras-raf-mek-erk Pathway Inhibitorsmentioning
confidence: 99%
“…Results showed a disease control rate (DCR) of 64.9% [13]. An interim analysis of a Phase II trial in which the combination of sorafenib and capecitabine was administered as second or later lines of chemotherapy in mCRC patients evidenced a median PFS of 4.4 months and 44% SD [14].…”
Section: Agonistic Trail Death Receptor Antibodies (Cont)mentioning
confidence: 99%